Literature DB >> 16842259

Pathological response of gastrointestinal stromal tumour to imatinib treatment correlates with tumour KIT mutational status in individual tumour clones.

M B Loughrey, V Beshay, A Dobrovic, J Zalcberg, P M Waring.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16842259     DOI： 10.1111/j.1365-2559.2006.02336.x

Source DB:  PubMed          Journal:  Histopathology        ISSN： 0309-0167            Impact factor:   5.087


× No keyword cloud information.
  2 in total

1.  Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.

Authors:  Michael C Heinrich; Robert G Maki; Christopher L Corless; Cristina R Antonescu; Amy Harlow; Diana Griffith; Ajia Town; Arin McKinley; Wen-Bin Ou; Jonathan A Fletcher; Christopher D M Fletcher; Xin Huang; Darrel P Cohen; Charles M Baum; George D Demetri
Journal:  J Clin Oncol       Date:  2008-10-27       Impact factor: 44.544

2.  Inactivity of imatinib in gastrointestinal stromal tumors (GISTs) harboring a KIT activation-loop domain mutation (exon 17 mutation pN822K).

Authors:  Gianluca Spitaleri; Roberto Biffi; Massimo Barberis; Caterina Fumagalli; Francesca Toffalorio; Chiara Catania; Cristina Noberasco; Chiara Lazzari; Filippo de Marinis; Tommaso De Pas
Journal:  Onco Targets Ther       Date:  2015-08-18       Impact factor: 4.147
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.